Outlook Therapeutics, Inc.OTLKNASDAQ
Loading
Operating Expenses Over TimeContracting
Percentile Rank75
3Y CAGR+2.8%
5Y CAGR+2.2%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+2.8%/yr
vs +4.6%/yr prior
5Y CAGR
+2.2%/yr
Consistent
Acceleration
-1.7pp
Decelerating
Percentile
P75
Within normal range
vs 5Y Ago
1.1x
Modest growth
Streak
2 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | $57.76M | -14.7% |
| 2025 | $67.72M | -5.6% |
| 2024 | $71.70M | +35.0% |
| 2023 | $53.13M | -15.5% |
| 2022 | $62.87M | +21.5% |
| 2021 | $51.73M | +50.3% |
| 2020 | $34.42M | -22.6% |
| 2019 | $44.45M | +35.8% |
| 2018 | $32.73M | -17.5% |
| 2017 | $39.69M | - |